Dr. Michael J. Naughton, MD

Dr. Naughton practices at Saint Francis Medical Center in Cape Girardeau, Missouri, part of Saint Francis Healthcare System.

Dr. Naughton's NPI, 1295752830, was assigned on July 17, 2006. Dr. Naughton graduated from State University of New York at Buffalo School of Medicine in 1993. Dr. Naughton holds Missouri license 103671.

Dr. Naughton's primary practice is Saint Francis Medical Center, at 211 St Francis Dr, Cape Girardeau, MO 63703 in Cape Girardeau County. The practice phone is (573) 331-3000.

Dr. Naughton's primary practice is Saint Francis Medical Center in Cape Girardeau, Missouri, part of Saint Francis Healthcare System. Dr. Naughton is also affiliated with Mercy Hospital Southeast. The medical group on file is Saint Francis Medical Center. Dmand AI also links Dr. Naughton to 3 more hospitals and 2 medical groups, each named with a free account. Dr. Naughton's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Naughton practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Naughton's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Naughton is licensed in Missouri.

CMS data shows 2,247 Medicare services from Dr. Naughton across 8 procedure codes in 2024, for 452 Medicare patients. Medicare paid $103,615 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 452 Medicare patients who saw Dr. Naughton in 2024. The largest group is 65 to 74, with 229 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Naughton's median patient age at 72, with 69% women.

In 2024, Dr. Naughton wrote 2,456 Medicare Part D claims for 334 patients. 85% of them were for generic drugs. CMS names the drug for 2,210 of them, across 46 drugs with 11 or more claims each, at $3,728,983 in total drug cost. In 2023, CMS named 1,677 claims across 38 drugs.

Dr. Naughton accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 5 papers to Dr. Naughton, published from 2014 to 2025. Dr. Naughton's most frequent co-author is Patrick Hoi Ginn Redmond, MD.

Dmand AI links Dr. Naughton to 1 clinical trial. Conditions studied include Breast Neoplasms and Breast Diseases. Open Payments lists research payments to Dr. Naughton that name 1 trial.

CMS Open Payments shows 956 general payments to Dr. Naughton from 51 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 71% of the total. Genentech, Inc. paid the most, $154,109. It also lists 1 research payment totaling $131 in 2016, naming 1 clinical trial.

Dr. Naughton graduated from State University of New York at Buffalo School of Medicine in 1993.